Lilly’s ultra rapid lispro provided similar A1C reductions compared to Humalog
INDIANAPOLIS — Two phase 3 studies show that Eli Lilly and Co.’s ultra rapid lispro (URLi) provided non-inferior A1C reductions compared to Humalog (insulin lispro) at 26 weeks in people with type 1 and type 2 diabetes. The data from these treat-to-target studies showed URLi also significantly reduced the rise in blood glucose one hour
